Invasive Hemodynamic Predictors of Outcomes in Rheumatic Heart Disease With Echocardiographic RV–PA Uncoupling: A Single‐Center Retrospective Cohort Study Authors: Raissa Rafidhinar, Jordan Budiono, Melawati Hasan, Triwedya Indra Dewi, Hawani Sasmaya Prameswari, Mohammad Rizki Akbar Published: 2026 ABSTRACT ABSTRACTRheumatic heart disease (RHD) is frequently complicated by pulmonary hypertension (PH) and right ventricular (RV) dysfunction. However, the prognostic significance of invasive hemodynamic parameters obtained at index right heart catheterization (RHC) in adults with RHD and echocardiographic RV–pulmonary artery (PA) uncoupling remains incompletely defined. We evaluated their associations with all‐cause mortality and a composite adverse clinical outcome. We conducted a single‐center retrospective cohort study of a clinically selected group of adults with RHD and echocardiographic RV–PA uncoupling who underwent index RHC for invasive hemodynamic assessment and pre‐intervention risk stratification. Parsimonious multivariable logistic regression models were used to examine adjusted associations between selected invasive hemodynamic variables and study outcomes during the available hospital‐record observation period. Among 56 patients, 14 (25.0%) died during the available hospital‐record observation period after the index RHC, and 23 (41.1%) experienced the composite adverse clinical outcome. In parsimonious multivariable analysis, higher pulmonary vascular resistance (PVR) remained associated with all‐cause mortality after adjustment (OR 1.573, 95% CI 1.012–2.447; p = 0.044), whereas lower RV fractional area change (FAC) (OR 0.885, 95% CI 0.814–0.962; p = 0.004) and lower right ventricular stroke work index (RVSWI) (OR 0.819, 95% CI 0.670–1.000; p = 0.020) remained associated with the composite adverse clinical outcome. All patients met hemodynamic criteria for combined pre‐ and post‐capillary pulmonary hypertension. In adults with RHD and echocardiographic RV–PA uncoupling who underwent clinically indicated invasive evaluation, higher PVR was associated with mortality, whereas lower FAC and lower RVSWI were associated with the composite adverse clinical outcome. These findings should be interpreted as exploratory associations derived from a clinically selected cohort and warrant confirmation in larger prospective studies.Keywords: pulmonary hypertension, pulmonary vascular resistance, right ventricular dysfunction, right ventricular stroke work index, risk stratification Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and premature mortality worldwide, particularly in low‐ and middle‐income countries. In low‐resource settings, RHD often affects younger patients, many of whom present with advanced valvular disease because of delayed diagnosis and limited access to definitive treatment. As the disease progresses, these patients may develop end‐stage heart failure, often with substantial cardiac damage, and may no longer be suitable candidates for heart transplantation or mechanical circulatory support. In advanced stages, right ventricle–pulmonary artery (RV–PA) uncoupling may occur, characterized by persistent right heart chamber enlargement and progressive right ventricular contractile failure in the setting of increased afterload [1, 2, 3]. In endemic settings, heart failure, pulmonary hypertension, and right‐sided dysfunction are closely associated with RHD, particularly in patients with chronic rheumatic mitral valve disease [3, 4, 5]. In RHD, chronic valvular lesions may lead to sustained elevation of left‐sided filling pressures that are transmitted backward to the pulmonary circulation, initially producing post‐capillary pulmonary hypertension (PH). Over time, a subset of patients develop superimposed pulmonary vascular remodeling, leading to increased pulmonary vascular load, greater right ventricular (RV) afterload, and progressive RV maladaptation [5, 6, 7]. This evolution from passive pulmonary venous congestion to combined pulmonary vascular and RV involvement is clinically important because symptoms, pre‐intervention assessment, and adverse outcomes are increasingly influenced not only by valve anatomy, but also by the pulmonary circulation and the ability of the RV to adapt to afterload [1, 6, 7]. Echocardiography remains the cornerstone of noninvasive assessment in valvular heart disease and PH [1, 2, 3]. Beyond conventional measures of RV systolic performance, RV–pulmonary artery (PA) coupling has emerged as a useful framework for evaluating RV adaptation to afterload. The Tricuspid Annular Plane Systolic Excursion (TAPSE)/Pulmonary Artery Systolic Pressure (PASP) (TAPSE/PASP) ratio has been validated as a practical echocardiographic surrogate of RV–PA coupling [8]. It has also shown prognostic relevance in valvular heart disease and RHD [7, 9]. In patients with RHD, this framework may be particularly relevant because chronic pressure and volume loading can generate a heterogeneous spectrum of RV dysfunction despite broadly similar clinical presentation [5, 6, 10]. Right heart catheterization (RHC), however, remains the reference standard for confirming PH and defining its hemodynamic profile [11, 12, 13]. In addition to direct measurement of right‐sided and pulmonary pressures and cardiac output, RHC provides derived indices that reflect pulmonary vascular load, RV performance, and right‐sided adaptation to load, including PVR, pulmonary arterial compliance (PAC), pulmonary artery pulsatility index (PAPi), right atrial pressure‐to‐pulmonary capillary wedge pressure (RAP/PCWP) ratio, and right ventricular stroke work index (RVSWI) [12, 13, 14, 15, 16, 17]. These variables may provide complementary hemodynamic characterization and additional prognostic information beyond echocardiography alone, particularly in patients who already demonstrate echocardiographic evidence of RV–PA uncoupling [12, 16, 18]. Despite growing interest in invasive hemodynamic phenotyping, the prognostic significance of index RHC‐derived parameters in adults with RHD remains insufficiently defined, especially in those with echocardiographic RV–PA uncoupling [5, 6, 18]. Existing evidence has largely focused on broader populations with PH or valvular heart disease, whereas data specifically addressing this clinically selected RHD subgroup are limited. Clarifying which invasive hemodynamic domains are most closely associated with subsequent adverse outcomes may improve risk stratification and clinical decision‐making, especially in settings where advanced rheumatic valvular disease remains prevalent. Therefore, we aimed to evaluate the associations of invasive hemodynamic parameters with all‐cause mortality and the composite adverse clinical outcome in adults with RHD who were selected for invasive evaluation on the basis of echocardiographic RV–PA uncoupling. Methods Study Design and Population This was a single‐center retrospective cohort study based on a registry‐derived cohort of adult patients with RHD, using secondary data from the Cardiac Surgery Division registry. The registry includes patients undergoing evaluation and management for clinically significant RHD with valvular and hemodynamic involvement, including echocardiographic assessment during clinical or pre‐intervention evaluation and invasive hemodynamic assessment when clinically indicated. Patients recorded in the registry between June 2022 and December 2025 were screened for eligibility. The study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Dr. Hasan Sadikin General Hospital, Bandung (protocol no. KP.04.04/D.XIV.3.4.23/271/2025). Because the study involved retrospective analysis of anonymized registry data, the requirement for informed consent was waived. All data were anonymized before analysis to protect patient confidentiality. This retrospective cohort included clinically selected adult patients with rheumatic heart disease and echocardiographic evidence of RV–PA uncoupling who subsequently underwent RHC as part of routine clinical care. In our institutional pathway, patients with RHD and echocardiographic RV–PA uncoupling were routinely scheduled for RHC to clarify pulmonary hemodynamics and support pre‐intervention risk stratification, irrespective of definitive operability. Patients were eligible for inclusion if they were aged ≥ 18 years, had confirmed rheumatic heart disease, had echocardiographic RV–PA uncoupling defined as TAPSE/PASP < 0.31 mm/mmHg, and underwent RHC as part of pre‐intervention hemodynamic evaluation. Patients were excluded if they had pulmonary hypertension attributable to causes other than RHD or complex congenital heart disease. No formal sample size calculation was performed because this was a retrospective registry‐based study. The sample size was determined by the number of consecutively eligible patients who met the prespecified inclusion and exclusion criteria during the study period. The participant selection process is summarized in Figure 1. Flow diagram of patient selection from the Cardiac Surgery Division registry between June 2022 and December 2025. Among 142 patients with valvular heart disease and echocardiographic RV–PA uncoupling who underwent right heart catheterization (RHC) for invasive hemodynamic assessment, 85 were excluded because they had non‐rheumatic valvular heart disease. Of the remaining 57 patients with rheumatic heart disease (RHD) screened for eligibility, one was excluded because of complex congenital heart disease with pulmonary hypertension attributable to causes other than RHD. The final analytic cohort comprised 56 adults with RHD, echocardiographic RV–PA uncoupling, and index RHC; of these, 36 subsequently underwent surgical intervention and 20 were managed without surgery. For exploratory subgroup comparisons, the cohort was also stratified into higher RVSWI (≥ 900 mmHg·mL/m2; n = 34) and lower RVSWI (< 900 mmHg·mL/m2; n = 22) groups. RVSWI, right ventricular stroke work index. In this study, echocardiographic RV–PA uncoupling served as the primary criterion prompting consideration for invasive hemodynamic evaluation. RHC was used to further characterize pulmonary hemodynamics, right‐sided filling pressures, and RV performance. To reduce information bias, echocardiographic and invasive hemodynamic measurements were obtained using standardized institutional protocols and were reviewed by certified cardiology personnel. Nevertheless, because the registry included only patients who underwent right heart catheterization, it did not capture non‐catheterized patients, including those with preserved RV–PA coupling and those with echocardiographic RV–PA uncoupling who did not undergo RHC. Therefore, the full denominator of potentially eligible patients could not be determined, which may introduce selection bias and limit generalizability to broader RHD populations. The date of RHC was defined as the index date for outcome ascertainment. In this cohort, RHC was performed to provide invasive hemodynamic clarification and inform pre‐intervention risk stratification, rather than to determine treatment strategy in isolation. The decision to proceed with surgery was based on multidisciplinary heart team assessment that incorporated valve lesion severity, invasive hemodynamic findings, right ventricular function, comorbidities, perioperative risk, overall operability, and, in some cases, patient preference following multidisciplinary evaluation and counseling. The analytic cohort therefore included both patients who subsequently underwent surgical intervention and those managed non‐surgically. Clinical outcomes were ascertained from the index RHC onward using institutional hospital records, including the index hospitalization and subsequent rehospitalizations, until the occurrence of the outcome of interest or the last available hospital‐record observation. Echocardiographic Assessment All patients underwent comprehensive echocardiography during clinical evaluation using a Vivid E95 cardiovascular ultrasound system (GE HealthCare, Horten, Norway) equipped with transthoracic and transesophageal phased‐array transducers. Image acquisition included two‐dimensional imaging, color Doppler, continuous‐wave Doppler, pulsed‐wave Doppler, and tissue Doppler imaging. The echocardiographic examination comprised characterization of rheumatic valvular involvement and assessment of RV–PA coupling. Valvular involvement was also categorized descriptively as isolated or mixed rheumatic valve disease. Right ventricular systolic function was evaluated using conventional echocardiographic parameters, including TAPSE and right ventricular FAC, when feasible [3]. RV–PA coupling was assessed using the TAPSE/PASP ratio, a practical echocardiographic surrogate of RV–PA coupling with established physiologic and prognostic relevance [3, 7, 8, 19]. PASP was estimated from the peak tricuspid regurgitation velocity using the simplified Bernoulli equation with the addition of estimated right atrial pressure, in accordance with current echocardiographic recommendations [3]. A reduced TAPSE/PASP ratio was considered to indicate echocardiographic RV–PA uncoupling. A cut‐off value of < 0.31 was adopted from prior validation studies in pulmonary hypertension populations and applied as an exploratory criterion in this analysis, given its physiologic and prognostic relevance despite the lack of disease‐specific validation in RHD and broader valvular heart disease populations [8]. Patients who met echocardiographic criteria for RV–PA uncoupling subsequently underwent right heart catheterization for invasive hemodynamic assessment as part of clinical evaluation. Doppler‐derived measurements were averaged over at least three cardiac cycles, and over five or more cycles in patients with atrial fibrillation. All acquired images and measurements were reviewed and validated by a certified cardiologist. Right Heart Catheterization and Invasive Hemodynamic Measurements All patients underwent RHC as part of clinical evaluation for invasive hemodynamic clarification and pre‐intervention risk assessment. The procedure was performed in the catheterization laboratory using a Swan–Ganz catheter inserted via the right internal jugular vein under ultrasound guidance. Resting measurements included right atrial pressure (RAP), right ventricular pressure (RVP), pulmonary artery pressure (PAP), pulmonary capillary wedge pressure (PCWP), and cardiac output (CO). CO was measured by thermodilution, and cardiac index (CI) was calculated by indexing CO to body surface area. PVR was calculated using standard formulas and expressed in Wood units. Additional derived variables included the RAP/PCWP ratio, RVSWI, PAPi, and PAC, which were used to characterize right‐sided hemodynamics, RV performance, pulmonary vascular load, and RV adaptation to afterload. Because universally accepted RVSWI cutoffs for RHD have not been established, RVSWI was primarily analyzed as a continuous invasive hemodynamic marker. For exploratory subgroup comparisons, patients were pragmatically stratified using an RVSWI threshold of 900 mmHg·mL/m2 to distinguish relatively lower vs. higher RV stroke work under increased pulmonary vascular load; this threshold was used for operational grouping rather than as a validated definition of RV dysfunction [20, 21]. Outcomes The primary outcomes were (1) all‐cause mortality and (2) a composite adverse clinical outcome, both assessed during the available hospital‐record observation period after the index right heart catheterization (RHC). All‐cause mortality was defined as death from any cause occurring after the index RHC and identified from institutional records during the available observation period. The composite adverse clinical outcome comprised cardiogenic shock, right ventricular (RV) failure, arrhythmia, and acute heart failure occurring after the index RHC and documented in institutional records, including events during the hospitalization in which surgery was performed, as well as during subsequent rehospitalizations among patients managed non‐surgically. This composite endpoint was intended as a pragmatic measure of overall clinical deterioration in this high‐risk cohort rather than to imply that all component events carried equivalent clinical weight. Given the limited sample size and event number, individual components were not modeled separately. Outcome ascertainment continued until the occurrence of the outcome of interest or the last available hospital‐record observation. Statistical Analysis Continuous variables are presented as mean ± standard deviation or median (interquartile range), as appropriate, and categorical variables as frequencies and percentages. Group comparisons were performed using the independent‐samples t‐test or Mann–Whitney U test for continuous variables and the Chi‐square test or Fisher's exact test for categorical variables, as appropriate. The primary outcomes were all‐cause mortality and the composite adverse clinical outcome, both assessed during the available observation period after the index right heart catheterization. Candidate variables were first evaluated using bivariable logistic regression and are reported as odds ratios (ORs) with 95% confidence intervals (CIs). Variable selection for multivariable analysis was based on both statistical associations and established clinical relevance. Accordingly, clinically relevant non‐invasive markers of right ventricular function, including fractional area change (FAC), were also considered in the final parsimonious models. Because RVSWI is measured on a relatively large numerical scale, it was modeled per 100 mmHg·mL/m2 increase to enhance the clinical interpretability of the estimated odds ratios. Multivariable logistic regression models were constructed parsimoniously given the limited number of outcome events, incorporating selected covariates representing distinct hemodynamic domains while minimizing inclusion of closely related variables within the same model. For all‐cause mortality, the adjusted model included FAC, RAP, and PVR to represent RV systolic performance, right‐sided filling pressure, and pulmonary vascular load, respectively. For the composite adverse clinical outcome, the adjusted model included FAC, RAP, RVSWI, and PVR to represent RV systolic performance, right‐sided congestion, RV functional reserve, and pulmonary vascular load. FAC and RVSWI were retained despite physiologic overlap because they were intended to capture complementary echocardiographic and invasive aspects of RV adaptation; however, this overlap may limit interpretability and underscores the exploratory nature of the model. All multivariable analyses were exploratory and intended to describe adjusted associations rather than establish a prognostic model. Because precise event dates, censoring dates, and complete longitudinal follow‐up outside the institutional record system were not consistently available, time‐to‐event analyses could not be reliably performed. Therefore, clinical outcomes were analyzed as binary events occurring during the available hospital‐record observation period after the index RHC. Logistic regression was used as a pragmatic exploratory approach to assess associations between invasive hemodynamic variables and clinical outcomes. Exploratory bivariable analyses were repeated after stratification by surgical treatment status. Given the limited number of events within each subgroup, multivariable modeling was not performed separately in the surgical or non‐surgical subgroup. All tests were two‐sided, and a p‐value < 0.05 was considered statistically significant. Data completeness was confirmed, with no missing data for variables included in the primary analyses. Statistical analyses were performed using IBM SPSS Statistics for Mac, version 29.0.2.0 (IBM Corp., Armonk, NY, USA). Results A total of 56 patients with RHD and echocardiographic RV–PA uncoupling were included in the final analysis. Surgical intervention was performed in 36 patients (64.3%), whereas 20 patients (35.7%) were managed non‐surgically. During the available observation period after the index RHC, 14 patients (25.0%) died and 23 (41.1%) developed the composite adverse clinical outcome. The composite adverse clinical outcome occurred in 23 patients and comprised acute heart failure (n = 5), arrhythmia (n = 3), cardiogenic shock (n = 7), and right ventricular failure (n = 8). These component events are reported descriptively only and are detailed in Supporting Information Table S1. Baseline clinical and echocardiographic characteristics are summarized in Table 1. Further detailed stratified data are provided in Supporting Information Table S2. The mean age of the cohort was 44.98 ± 10.6 years, 33 patients (58.9%) were women, and mixed rheumatic valve involvement was present in 50 patients (89.3%). In the exploratory RVSWI subgroup analysis, patients in the lower RVSWI group also had significantly lower PASP (65.08 ± 20.9 vs. 78.41 ± 23.8 mmHg; p = 0.037) and lower TRVmax (3.29 ± 0.5 vs. 3.86 ± 0.6 m/s; p < 0.001) than those in the higher RVSWI group. When stratified by outcome status (Table 2), patients who died had significantly lower FAC than survivors (25.14 ± 12.9 vs. 32.95 ± 10.7; p = 0.029). Similarly, patients who developed the composite adverse clinical outcome had significantly lower FAC than those without such events (24.39 ± 10.7 vs. 35.59 ± 10.2; p < 0.001). TABLE 1Baseline clinical and echocardiographic characteristics by RVSWI group.VariableAll patients (n = 56)Higher RVSWI (≥ 900 mmHg·mL/m2) (n = 34)Lower RVSWI (< 900 mmHg·mL/m2) (n = 22) p‐valueAge, years44.98 ± 10.644.38 ± 11.545.91 ± 9.20.681Sex, n (%)0.091Male23 (41.1%)17 (50.0%)6 (27.3%)Female33 (58.9%)17 (50.0%)16 (72.7%)BMI, n (%)0.554Normal36 (64.3%)20 (58.8%)16 (72.7%)Underweight13 (23.2%)9 (26.5%)4 (18.2%)Overweight5 (8.9%)3 (8.8%)2 (9.1%)Obesity grade 12 (3.6%)2 (5.9%)0 (0.0%)Obesity grade 20 (0.0%)0 (0.0%)0 (0.0%)NYHA functional class0.681II29 (51.8%)18 (52.9%)11 (50.0%)III26 (46.4%)15 (44.1%)11 (50.0%)IV1 (1.8%)1 (2.9%)0 (0.0%)ECG rhythm0.418Sinus rhythm14 (25.0%)8 (23.5%)6 (27.3%)Atrial fibrillation41 (73.2%)26 (76.5%)15 (68.2%)Atrial flutter1 (1.8%)0 (0.0%)1 (4.5%)EchocardiographyTAPSE/PASP0.23 ± 0.10.22 ± 0.10.25 ± 0.10.105TAPSE14.00 (7.4–24.0)14.00 (8.0–21.0)13.12 (7.4–24.0)0.681FAC30.99 ± 11.732.14 ± 10.729.22 ± 13.190.368PASP73.17 ± 23.578.41 ± 23.865.08 ± 20.9 0.037 TRVmax3.64 ± 0.63.86 ± 0.63.29 ± 0.5 < 0.001 RV base45.71 ± 8.144.23 ± 7.648.00 ± 8.50.089LAVI98.32 (17.4–962.1)99.32 (64.7–148.0)97.40 (17.4–962.1)0.250LVEF55.29 ± 13.456.29 ± 12.453.73 ± 15.10.490Valvular involvement pattern, n (%)1.000Isolated valve disease6 (10.7%)4 (11.8%)2 (9.1%)Mixed valve disease50 (89.3%)30 (88.2%)20 (90.9%)Subsequent surgery after index RHC0.514Surgical36 (64.3%)23 (67.6%)13 (59.1%)Non‐surgical20 (35.7%)11 (32.4%)9 (40.9%) Note: Categorical data are presented as number (%) and were compared using the Chi‐square test or Fisher's exact test, as appropriate. Continuous data with a normal distribution are presented as mean ± standard deviation and were compared using the independent‐samples t‐test. Continuous data with a non‐normal distribution are presented as median (interquartile range) and were compared using the Mann–Whitney U test. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold.Abbreviations: BMI, body mass index; ECG, electrocardiography; FAC, fractional area change; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RV, right ventricular; RVSWI, right ventricular stroke work index; TAPSE, tricuspid annular plane systolic excursion; TRVmax, maximum tricuspid regurgitation velocity. Baseline clinical and echocardiographic characteristics by RVSWI group. Note: Categorical data are presented as number (%) and were compared using the Chi‐square test or Fisher's exact test, as appropriate. Continuous data with a normal distribution are presented as mean ± standard deviation and were compared using the independent‐samples t‐test. Continuous data with a non‐normal distribution are presented as median (interquartile range) and were compared using the Mann–Whitney U test. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold. Abbreviations: BMI, body mass index; ECG, electrocardiography; FAC, fractional area change; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RV, right ventricular; RVSWI, right ventricular stroke work index; TAPSE, tricuspid annular plane systolic excursion; TRVmax, maximum tricuspid regurgitation velocity. TABLE 2Baseline clinical and echocardiographic characteristics by outcome status.VariableAll patients (n = 56)Mortality (n = 14)No mortality (n = 42) p‐valueAdverse clinical outcome (n = 23)No adverse clinical outcome (n = 33) p‐valueAge, years44.98 ± 10.646.29 ± 9.144.55 ± 11.10.59946.83 ± 7.843.69 ± 12.10.279Sex, n (%)0.4330.159Male23 (41.1%)7 (50.0%)16 (38.1%)12 (52.2%)11 (33.3%)Female33 (58.9%)7 (50.0%)26 (61.9%)11 (47.8%)22 (66.7%)BMI, n (%)0.3120.756Normal36 (64.3%)11 (78.6%)25 (59.5%)16 (69.6%)20 (60.6%)Underweight13 (23.2%)2 (14.3%)11 (26.2%)5 (21.7%)8 (24.2%)Overweight5 (8.9%)0 (0.0%)5 (11.9%)1 (4.3%)4 (12.1%)Obesity grade 12 (3.6%)1 (7.1%)1 (2.4%)1 (4.3%)1 (3.0%)Obesity grade 20 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)0 (0.0%)NYHA functional class0.0830.161II29 (51.8%)3 (21.4%)26 (61.9%)9 (39.1%)20 (60.6%)III26 (46.4%)11 (78.6%)15 (35.7%)14 (60.9%)12 (36.4%)IV1 (1.8%)0 (0.0%)1 (2.4%)0 (0.0%)1 (3.0%)ECG rhythm0.2120.467Sinus rhythm14 (25.0%)3 (21.4%)11 (26.2%)6 (26.1%)8 (24.2%)Atrial fibrillation41 (73.2%)10 (71.4%)31 (73.8%)16 (69.6%)25 (75.8%)Atrial flutter1 (1.8%)1 (7.1%)0 (0.0%)1 (4.3%)0 (0.0%)EchocardiographyTAPSE/PASP0.23 ± 0.10.23 ± 0.10.24 ± 0.10.6790.24 ± 0.10.23 ± 0.10.625TAPSE14.00 (7.4–24.0)13.79 (9.7–21.0)14.00 (7.4–24.0)0.67914.00 (8.0–21.0)14.00 (7.4–24.0)0.609FAC30.99 ± 11.725.14 ± 12.932.95 ± 10.7 0.029 24.39 ± 10.735.59 ± 10.2 < 0.001 PASP73.17 ± 23.578.79 ± 17.771.30 ± 24.90.30676.19 ± 18.671.06 ± 26.40.426TRVmax3.64 ± 0.63.59 ± 0.83.66 ± 0.60.7433.56 ± 0.73.70 ± 0.60.408RV base45.71 ± 8.147.36 ± 9.445.17 ± 7.70.38547.43 ± 8.544.52 ± 7.70.187LAVI98.32 (17.4–962.1)106.60 (64.7–148.0)87.45 (17.4–962.1)0.508106.00 (54.6–148.0)89.90 (17.4–962.1)0.934LVEF55.29 ± 13.463.50 ± 8.852.55 ± 13.7 0.007 53.30 ± 17.256.67 ± 10.10.362Valvular involvement pattern, n (%)0.6331.000Isolated valve disease6 (10.7%)2 (14.3%)4 (9.5%)2 (8.7%)4 (12.1%)Mixed valve disease50 (89.3%)12 (85.7%)38 (90.5%)21 (91.3%)29 (87.9%)Subsequent surgery after index RHC1.0000.903Yes36 (64.3%)9 (64.3%)27 (64.3%)15 (65.4%)21 (63.6%)No20 (35.7%)5 (35.7%)15 (35.7%)8 (34.8%)12 (36.4%) Note: Categorical data are presented as number (%) and were compared using the Chi‐square test or Fisher's exact test, as appropriate. Continuous data with a normal distribution are presented as mean ± standard deviation and were compared using the independent‐samples t‐test. Continuous data with a non‐normal distribution are presented as median (interquartile range) and were compared using the Mann–Whitney U test. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold.Abbreviations: BMI, body mass index; ECG, electrocardiography; FAC, fractional area change; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion; TRVmax, maximum tricuspid regurgitation velocity. Baseline clinical and echocardiographic characteristics by outcome status. Note: Categorical data are presented as number (%) and were compared using the Chi‐square test or Fisher's exact test, as appropriate. Continuous data with a normal distribution are presented as mean ± standard deviation and were compared using the independent‐samples t‐test. Continuous data with a non‐normal distribution are presented as median (interquartile range) and were compared using the Mann–Whitney U test. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold. Abbreviations: BMI, body mass index; ECG, electrocardiography; FAC, fractional area change; LAVI, left atrial volume index; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PASP, pulmonary artery systolic pressure; RV, right ventricular; TAPSE, tricuspid annular plane systolic excursion; TRVmax, maximum tricuspid regurgitation velocity. The invasive hemodynamic profile according to RVSWI subgroup is shown in Table 3. Patients in the lower RVSWI group had significantly lower cardiac output (CO) (3.51 ± 0.8 vs. 4.13 ± 0.9 L/min; p = 0.010), cardiac index (CI) (2.35 ± 0.4 vs. 2.75 ± 0.6 L/min/m2; p = 0.008), RVSWI (646.78 ± 184.2 vs. 1448.24 ± 419.9; p < 0.001), and PAPi (3.71 [1.03–20.00] vs. 4.91 [2.67–13.14]; p = 0.005) than those in the higher RVSWI group. In contrast, RAP, PAP, PCWP, PAC, RAP/PCWP ratio, and PVR did not differ significantly between groups. All patients fulfilled hemodynamic criteria for combined pre‐ and post‐capillary pulmonary hypertension. Because universally accepted RVSWI cutoffs for RHD have not been established, the 900 mmHg·mL/m2 threshold was used for exploratory descriptive subgrouping only. TABLE 3Baseline invasive hemodynamics by RVSWI group.VariableHigher RVSWI (≥ 900 mmHg·mL/m2) (n = 34)Lower RVSWI (< 900 mmHg·mL/m2) (n = 22) p‐valueRAP8.50 (2.00–20.00)8.50 (1.00–34.00)0.429PAP41.00 ± 12.346.09 ± 13.30.156PCWP24.41 ± 6.625.09 ± 6.70.711CO4.13 ± 0.93.51 ± 0.8 0.010 CI2.75 ± 0.62.35 ± 0.4 0.008 RVSWI1448.24 ± 419.9646.78 ± 184.2 < 0.001 PAPi4.91 (2.67–13.14)3.71 (1.03–20.00) 0.005 PAC1.27 (0.42–3.80)1.15 (0.40–2.34)0.421RAP/PCWP0.38 (0.07–0.76)0.39 (0.14–1.12)0.445PVR6.13 ± 2.726.79 ± 4.70.508Pulmonary hypertension (PH)0.689Pre‐capillary PH0 (0.0%)0 (0.0%)Post‐capillary PH0 (0.0%)0 (0.0%)Combined pre‐ and post‐capillary PH34 (100.0%)22 (100.0%) Note: Categorical data are presented as number (%) and were compared using the Chi‐square test or Fisher's exact test, as appropriate. Continuous data with a normal distribution are presented as mean ± standard deviation and were compared using the independent‐samples t‐test. Continuous data with a non‐normal distribution are presented as median (interquartile range) and were compared using the Mann–Whitney U test. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold.Abbreviations: CI, cardiac index; CO, cardiac output; PAC, pulmonary arterial compliance; PAP, pulmonary artery pressure; PAPi, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index. Baseline invasive hemodynamics by RVSWI group. Note: Categorical data are presented as number (%) and were compared using the Chi‐square test or Fisher's exact test, as appropriate. Continuous data with a normal distribution are presented as mean ± standard deviation and were compared using the independent‐samples t‐test. Continuous data with a non‐normal distribution are presented as median (interquartile range) and were compared using the Mann–Whitney U test. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold. Abbreviations: CI, cardiac index; CO, cardiac output; PAC, pulmonary arterial compliance; PAP, pulmonary artery pressure; PAPi, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index. Bivariable logistic regression analyses for all‐cause mortality are summarized in Table 4. Higher RAP, PAP, and PVR were associated with increased odds of death, whereas higher PAPi and PAC were associated with lower odds of mortality. In the parsimonious multivariable model, including FAC, RAP, and PVR, only higher PVR remained associated with all‐cause mortality (OR 1.573, 95% CI 1.012–2.447; p = 0.044), whereas FAC (OR 0.933, 95% CI 0.853–1.022; p = 0.136) and RAP (OR 1.038, 95% CI 0.878–1.227; p = 0.655) were not associated with the outcome (Table 5). Given the limited number of mortality events, these adjusted estimates should be interpreted cautiously. TABLE 4Bivariable predictors of all‐cause mortality.VariableBivariable analysisOR (95% CI) (n = 56) p‐valueRAP (per 1 mmHg)1.178 (1.047–1.325) 0.006 PAP (per 1 mmHg)1.058 (1.004–1.114) 0.035 PCWP (per 1 mmHg)1.056 (0.961–1.161)0.254CO (per 1 L/min)0.535 (0.247–1.164)0.114CI (per 1 L/min/m2)0.482 (0.148–1.568)0.225RVSWI (per 100 mmHg·mL/m2)1.000 (0.819–1.221)0.146PAPi (per 1)0.662 (0.456–0.960) 0.029 PAC (per 1 mL/mmHg)0.245 (0.061–0.983) 0.047 RAP/PCWP (per 1)18.583 (0.829–416.734)0.066PVR (per 1 WU)1.189 (1.066–1.407) 0.003 FAC (per 1%)0.936 (0.879–0.996) 0.037 Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using bivariable logistic regression for all‐cause mortality. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold.Abbreviations: CI, confidence interval; CO, cardiac output; OR, odds ratio; PAC, pulmonary arterial compliance; PAP, pulmonary artery pressure; PAPi, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; WU, Wood units. Bivariable predictors of all‐cause mortality. Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using bivariable logistic regression for all‐cause mortality. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold. Abbreviations: CI, confidence interval; CO, cardiac output; OR, odds ratio; PAC, pulmonary arterial compliance; PAP, pulmonary artery pressure; PAPi, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; WU, Wood units. TABLE 5Multivariable predictors of all‐cause mortality.VariableMultivariable analysisOR (95% CI) (n = 56) p‐valueFAC (per 1%)0.933 (0.853–1.022)0.136RAP (per 1 mmHg)1.038 (0.878–1.227)0.655PVR (per 1 WU)1.573 (1.012–2.447) 0.044 Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a parsimonious multivariable logistic regression model for all‐cause mortality. The adjusted model included FAC, RAP, and PVR. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold.Abbreviations: CI, confidence interval; FAC, fractional area change; OR, odds ratio; PVR, pulmonary vascular resistance; RAP, right atrial pressure; WU, Wood units. Multivariable predictors of all‐cause mortality. Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a parsimonious multivariable logistic regression model for all‐cause mortality. The adjusted model included FAC, RAP, and PVR. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold. Abbreviations: CI, confidence interval; FAC, fractional area change; OR, odds ratio; PVR, pulmonary vascular resistance; RAP, right atrial pressure; WU, Wood units. Bivariable logistic regression analyses for the composite adverse clinical outcome are presented in Table 6. Higher RAP and PVR were associated with increased odds of adverse outcomes, whereas higher RVSWI (expressed per 100 mmHg·mL/m2 increase), PAPi, and PAC were associated with lower odds. In the parsimonious multivariable model, including FAC, RAP, RVSWI, and PVR, lower FAC (OR 0.885, 95% CI 0.814–0.962; p = 0.004) and lower RVSWI (expressed per 100 mmHg·mL/m2 increase; OR 0.819, 95% CI 0.670–1.000; p = 0.016) remained associated with the composite adverse clinical outcome, whereas RAP (OR 1.126, 95% CI 0.974–1.302; p = 0.109) and PVR (OR 1.117, 95% CI 0.860–1.452; p = 0.406) were not statistically significant (Table 7). Given the limited number of events, these adjusted estimates should be interpreted cautiously. The association between RVSWI and the composite adverse clinical outcome remained statistically significant after expressing RVSWI per 100 mmHg·mL/m2 increase, thereby improving the interpretability of the effect estimate without altering the overall findings. TABLE 6Bivariable predictors of the composite adverse clinical outcome.VariableBivariable analysis OR (95% CI) (n = 56) p‐valueRAP (per 1 mmHg)1.151 (1.030–1.286) 0.013 PAP (per 1 mmHg)1.032 (0.989–1.077)0.149PCWP (per 1 mmHg)1.052 (0.968–1.144)0.233CO (per 1 L/min)0.702 (0.375–1.312)0.267CI (per 1 L/min/m2)0.539 (0.197–1.472)0.228RVSWI (per 100 mmHg·mL/m2)0.819 (0.740–1.000) 0.011 PAPi (per 1)0.756 (0.587–0.973) 0.030 PAC (per 1 mL/mmHg)0.350 (0.127–0.966) 0.043 RAP/PCWP (per 1)7.453 (0.432–128.450)0.167PVR (per 1 WU)1.191 (1.003–1.414) 0.036 FAC (per 1%)0.899 (0.842–0.960) 0.001 Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using bivariable logistic regression for the composite adverse clinical outcome. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold.Abbreviations: CI, confidence interval; CO, cardiac output; OR, odds ratio; PAC, pulmonary arterial compliance; PAP, pulmonary artery pressure; PAPi, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; WU, Wood units. Bivariable predictors of the composite adverse clinical outcome. OR (95% CI) (n = 56) Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using bivariable logistic regression for the composite adverse clinical outcome. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold. Abbreviations: CI, confidence interval; CO, cardiac output; OR, odds ratio; PAC, pulmonary arterial compliance; PAP, pulmonary artery pressure; PAPi, pulmonary artery pulsatility index; PCWP, pulmonary capillary wedge pressure; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; WU, Wood units. TABLE 7Multivariable predictors of the composite adverse clinical outcome.VariableMultivariable analysisOR (95% CI) (n = 56) p‐valueFAC (per 1%)0.885 (0.814–0.962) 0.004 RAP (per 1 mmHg)1.126 (0.974–1.302)0.109RVSWI (per 100 mmHg·mL/m2)0.819 (0.670–1.000) 0.020 PVR (per 1 WU)1.117 (0.860–1.452)0.406 Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a parsimonious multivariable logistic regression model for the composite adverse clinical outcome. The adjusted model included FAC, RAP, RVSWI, and PVR. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold.Abbreviations: CI, confidence interval; FAC, fractional area change; OR, odds ratio; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; WU, Wood units. Multivariable predictors of the composite adverse clinical outcome. Note: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated using a parsimonious multivariable logistic regression model for the composite adverse clinical outcome. The adjusted model included FAC, RAP, RVSWI, and PVR. ORs are presented per unit increase as specified for each variable. All tests were two‐sided, and p < 0.05 was considered statistically significant are in bold. Abbreviations: CI, confidence interval; FAC, fractional area change; OR, odds ratio; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RVSWI, right ventricular stroke work index; WU, Wood units. Exploratory subgroup analyses according to surgical treatment status are summarized in Supporting Information Tables S2–S7. In the surgically treated subgroup, invasive hemodynamic profiles according to RVSWI group are shown in Supporting Information Table S2. Bivariable analysis identified higher RAP and PAP and lower PAPi as variables associated with all‐cause mortality, whereas lower PAPi and lower PAC were associated with the composite adverse clinical outcome (Supporting Information Tables S3 and S4). In the non‐surgically treated subgroup, patients with lower RVSWI had lower cardiac output and PAPi, with no significant differences in RAP, PAP, PCWP, PAC, RAP/PCWP ratio, or PVR between RVSWI groups (Supporting Information Table S5). In bivariable analyses, no invasive hemodynamic parameter was significantly associated with all‐cause mortality or the composite adverse clinical outcome in the non‐surgically treated subgroup (Supporting Information Tables S6 and S7). Clinical outcomes according to surgical treatment status are summarized in Supporting Information Table S8. All‐cause mortality was identical between surgically and non‐surgically treated patients (25.0% vs. 25.0%, p = 1.000), and the composite adverse clinical outcome was also similar between groups (41.7% vs. 40.0%, p = 0.903). No individual component of the composite outcome differed significantly according to surgical status. Clinical outcomes according to RVSWI group are presented in Supporting Information Table S9. The composite adverse clinical outcome occurred more frequently in patients with lower RVSWI than in those with higher RVSWI (68.2% vs. 23.5%, p = 0.002). Among the individual components, right ventricular failure was significantly more frequent in the lower RVSWI group (31.8% vs. 2.9%, p = 0.004), whereas all‐cause mortality, cardiogenic shock, arrhythmia, and acute heart failure did not differ significantly between RVSWI groups. Because of the restricted subgroup sample sizes and limited number of events, these analyses should be regarded as exploratory and hypothesis‐generating. Discussion This retrospective cohort of patients with RHD and echocardiographic RV–PA uncoupling who subsequently underwent RHC for invasive hemodynamic assessment highlights three main findings. First, this was a clinically selected RHD population in whom echocardiography suggested impaired RV adaptation, while RHC provided complementary invasive hemodynamic characterization beyond noninvasive assessment [3, 12]. Although baseline clinical characteristics were broadly similar, invasive assessment more clearly identified differences in forward flow and RV functional reserve [12, 13], supporting the presence of hemodynamic heterogeneity within this cohort. Second, all‐cause mortality and the composite adverse clinical outcome appeared to be associated with different hemodynamic domains. In parsimonious multivariable models, PVR remained associated with all‐cause mortality, whereas lower FAC and lower RVSWI were associated with the composite adverse clinical outcome. Third, these findings should be interpreted in the context of a real‐world cohort referred for invasive hemodynamic clarification and risk stratification, rather than as evidence that echocardiographic RV–PA uncoupling represents a single uniform invasive phenotype [12, 13]. In this context, RHC is best viewed as an adjunctive tool for hemodynamic clarification and risk stratification rather than a standalone determinant of treatment strategy [2, 12, 13]. Management strategy itself may nevertheless have influenced subsequent outcomes, because surgery may have acted both as a confounder by indication and as a modifier of later risk. Although the TAPSE/PASP ratio has been validated as a noninvasive surrogate of right ventricular–pulmonary arterial (RV–PA) coupling in pulmonary hypertension populations, patients meeting the echocardiographic uncoupling threshold should not be assumed to share the same invasive hemodynamic profile. In this study, a cutoff value of < 0.31 was used based on prior validation studies in pulmonary hypertension and applied in an exploratory manner, as disease‐specific validation in rheumatic and valvular heart disease populations remains limited [8]. RHC therefore remains valuable because it directly characterizes pulmonary vascular load, right‐sided filling pressures, and RV pump performance [12, 13]. All patients in our cohort fulfilled hemodynamic criteria for combined pre‐ and post‐capillary pulmonary hypertension under contemporary definitions, consistent with a relatively advanced hemodynamic state in which elevated left‐sided filling pressures coexisted with pulmonary vascular involvement [5, 6, 11]. The focus on RHD was clinically relevant because rheumatic valve disease commonly presents with advanced valvular involvement, pulmonary hypertension, and right‐heart abnormalities; however, our findings should not be interpreted as establishing an RHD‐specific hemodynamic pattern [4, 6, 10]. This is also consistent with recent valvular heart disease data showing that baseline combined pre‐ and post‐capillary PH is associated with a higher likelihood of persistent PH after valve intervention [18]. In an exploratory descriptive subgroup analysis, the finding that patients in the lower RVSWI group demonstrated lower PASP and TRVmax may appear counterintuitive, but it is physiologically plausible because pulmonary pressure estimates reflect not only afterload but also the ability of the right ventricle to generate systolic pressure and maintain forward flow [3, 12, 13]. As right ventricular contractile reserve declines, measurable pulmonary pressures may decrease despite persistent or advanced hemodynamic disease. The observation of higher LVEF in the mortality group is also unexpected but likely reflects the limitations of LVEF as an index of global cardiac performance in rheumatic and valvular heart disease. In this context, preserved or even higher LVEF may coexist with significant right ventricular dysfunction, elevated filling pressures, and adverse ventricular interdependence. Accordingly, LVEF may not reliably reflect overall hemodynamic severity or clinical risk in this population and should be interpreted cautiously when assessed in isolation. Pulmonary pressure estimates reflect not only afterload but also the ability of the RV to generate systolic pressure and maintain forward flow [3, 12, 13]. As RV adaptation begins to fail, declining contractile reserve may contribute to lower measurable PASP despite persistent hemodynamic burden. In our cohort, the concomitant reductions in CO, CI, RVSWI, and PAPi support the interpretation that invasive hemodynamic compromise was more closely related to impaired RV adaptation and reduced forward flow than to pressure elevation alone [12, 13]. This physiologic framework may also help explain why FAC, but not TAPSE, was associated with outcomes in our cohort. FAC incorporates both longitudinal and radial components of RV contraction and may better reflect global RV systolic performance under abnormal loading conditions, whereas TAPSE reflects predominantly longitudinal shortening alone. This pattern is consistent with prior work highlighting the clinical relevance of RV–PA interaction across disease state, including valvular heart disease and heart failure. Wu et al. emphasized its prognostic significance in valvular heart disease, whereas Yao et al. summarized its clinical and prognostic relevance in heart failure [7, 19]. Although the present study primarily focused on invasive hemodynamic assessment, retention of FAC in the final multivariable model is supported by prior evidence. Gumus et al. demonstrated an association between RV‐FAC and invasive measures of right ventricular performance, including the right ventricular stroke work index (RVSWI), suggesting that echocardiographic and invasive hemodynamic assessments reflect related aspects of right ventricular function [22]. Nevertheless, FAC should not be regarded as a substitute for invasive hemodynamic assessment. Rather, echocardiographic and RHC‐derived parameters may provide complementary information regarding right ventricular performance. Among the invasive variables examined, PVR was the only parameter that remained associated with mortality after multivariable adjustment in our cohort. This finding suggests that mortality may be more strongly associated with pulmonary vascular remodeling and relatively fixed pulmonary vascular load than with pressure measurements alone, consistent with prior studies demonstrating the adverse prognostic significance of elevated PVR. Palazzini et al. reported worse survival in pulmonary hypertension due to left heart disease when pulmonary vascular resistance was elevated, whereas Bermejo et al. identified higher pulmonary vascular resistance as a key factor associated with mortality in persistent pulmonary hypertension after corrected valvular heart disease [23, 24]. In our model, the odds ratio for PVR was expressed per 1 Wood unit increase, indicating an incremental adverse association with greater pulmonary vascular load rather than a single threshold effect. Notably, although PVR did not differ significantly between the higher and lower RVSWI groups at baseline, it remained associated with mortality, suggesting that its prognostic relevance may persist even when cross‐sectional between‐group differences are not apparent within a relatively homogeneous cohort. Nevertheless, these adjusted findings should be interpreted cautiously because the number of mortality events was limited relative to model complexity. In contrast, lower FAC and lower RVSWI remained associated with the composite adverse clinical outcome, suggesting that clinical deterioration during the available observation period may be more closely related to impaired RV systolic performance and reduced RV functional reserve than to pulmonary vascular load alone. FAC is an established echocardiographic index of global RV systolic performance, whereas RVSWI reflects the mechanical work generated by the RV against its afterload [3, 13, 21]. Taken together, these findings suggest that, among patients selected by echocardiographic RV–PA uncoupling, the composite adverse clinical outcome may be more closely linked to impaired RV systolic adaptation and reduced capacity to sustain forward flow under hemodynamic load. Because the composite included heterogeneous events of differing clinical severity, it should be interpreted as an exploratory pragmatic measure of overall clinical deterioration rather than as a group of equally weighted hard outcomes. This may also help explain why FAC and RVSWI were associated with the composite adverse clinical outcome but not with mortality alone, suggesting closer relationships with non‐fatal hemodynamic decompensation and short‐term clinical worsening. The subgroup analysis restricted to surgically treated patients should nevertheless be interpreted cautiously, given the smaller sample size and lower event count. Accordingly, these findings should be considered exploratory and hypothesis‐generating rather than definitive. The potential influence of surgical intervention on outcomes should also be carefully considered. In this cohort, decisions regarding surgical intervention were based on multidisciplinary heart team assessment, incorporating clinical presentation, valve lesion characteristics, hemodynamic findings, right ventricular function, and overall operability. As such, treatment allocation was not randomized and may have introduced confounding by indication, whereby patients selected for surgery may have differed systematically from those managed non‐surgically in ways not fully captured by the available variables. Although an exploratory sensitivity analysis restricted to the surgically treated subgroup was performed, the limited sample size and number of events precluded more robust adjustment for treatment effects or formal evaluation of interaction between surgical status and hemodynamic predictors. Accordingly, the observed associations of PVR, FAC, and RVSWI with clinical outcomes should be interpreted with caution, as they may partly reflect underlying differences in treatment pathways. Future studies with larger cohorts and more comprehensive adjustment for treatment allocation are needed to better define the prognostic role of invasive hemodynamic parameters in this setting. Strengths and Limitations This study provides invasive hemodynamic data in an underrepresented population of patients with rheumatic heart disease (RHD) and echocardiographic RV–pulmonary artery (PA) uncoupling, and is strengthened by the use of right heart catheterization (RHC) for direct hemodynamic assessment. Several limitations should nevertheless be considered. First, this was a single‐center retrospective study with a limited sample size, which may have reduced statistical precision and limited the generalizability of the findings. Second, because inclusion occurred after referral for and performance of RHC, the cohort represents a clinically selected subgroup; patients outside this invasive pathway were not captured in the registry and therefore could not be systematically evaluated. Third, the cohort included both surgically treated and non‐surgically managed patients, reflecting real‐world clinical practice but also introducing treatment heterogeneity; surgery may have acted as both a confounder by indication and a modifier of subsequent risk. Fourth, the composite adverse clinical outcome comprised heterogeneous events of differing severity, and although its individual components are reported descriptively, the composite should still be interpreted as an exploratory pragmatic measure of overall clinical deterioration. Fifth, outcome ascertainment was based on the available hospital‐record observation period after the index RHC rather than on standardized prospective follow‐up; accordingly, differences in observation time could not be fully accounted for, events outside the institutional record system may have been missed, and robust time‐to‐event analyses could not be performed. Sixth, because all patients had combined pre‐ and post‐capillary pulmonary hypertension, the findings may be most applicable to clinically selected adults with advanced RHD undergoing invasive hemodynamic evaluation. In addition, invasive RV–PA coupling was not directly quantified using gold‐standard pressure–volume methods such as Ees/Ea, and the hemodynamic variables examined should therefore be interpreted as invasive markers of pulmonary vascular load, right‐sided filling pressures, and RV performance rather than as direct validated measures of RV–PA coupling. A further limitation relates to model interpretability. The limited number of outcome events relative to the number of covariates, the clinical heterogeneity of the composite endpoint, and the physiologic overlap between FAC and RVSWI may have influenced model interpretability. Therefore, the adjusted associations should be regarded as exploratory. Because FAC and RVSWI assess related aspects of RV functional reserve through complementary echocardiographic and invasive hemodynamic domains, these findings should be interpreted as concordant markers of impaired RV performance rather than as fully independent prognostic effects. Within these limitations, index RHC provided complementary invasive hemodynamic characterization in patients with RHD and echocardiographic RV–PA uncoupling. Higher PVR was associated with all‐cause mortality, whereas lower FAC and lower RVSWI were associated with the composite adverse clinical outcome. These findings suggest that, in this clinically selected population, mortality may be more closely related to pulmonary vascular load, whereas non‐fatal clinical deterioration may be more closely linked to impaired RV adaptation and reduced functional reserve. These observations should be interpreted cautiously and require confirmation in larger multicenter cohorts with standardized follow‐up. Future studies should evaluate whether integrating echocardiographic RV–PA uncoupling with invasive hemodynamic markers improves risk stratification in advanced RHD. Author Contributions Raissa Rafidhinar conceived the study, collected the data, contributed to study design and data interpretation, and drafted the manuscript. Jordan Budiono performed the statistical analysis and contributed to interpretation of the results. Melawati Hasan contributed to echocardiographic data interpretation and critically revised the manuscript. Triwedya Indra Dewi contributed to outcome data interpretation and critically revised the manuscript. Hawani Sasmaya Prameswari and Mohammad Rizki Akbar contributed to invasive hemodynamic interpretation, supervised the study, and critically revised the manuscript for important intellectual content. All authors read and approved the final manuscript. Ethics Statement The study was conducted in accordance with the Declaration of Helsinki and was approved by the Research Ethics Committee of Dr. Hasan Sadikin General Hospital, Bandung (protocol no. KP.04.04/D.XIV.3.4.23/271/2025). Because this study involved retrospective analysis of anonymized registry data, the requirement for informed consent was waived by the ethics committee. Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Supplementary Tables S1–S9: are provided as a separate XLSX file. These include descriptive reporting of overall clinical outcomes and components of the composite adverse clinical outcome, exploratory subgroup analyses according to surgical treatment status, clinical outcomes according to surgical treatment status, and clinical outcomes according to RVSWI group. Supporting information Table S1: Overall clinical outcomes and descriptive components of the composite adverse clinical outcome. Table S2: Invasive Hemodynamics by RVSWI Group in the Surgically Treated Subgroup. Table S3: Bivariable Predictors of All‐Cause Mortality in the Surgically Treated Subgroup. Table S4: Bivariable Predictors of the Composite Adverse Clinical Outcome in the Surgically Treated Subgroup. Table S5: Invasive Hemodynamics by RVSWI Group in the Non‐surgically Treated Subgroup. Table S6: Bivariable Predictors of All‐Cause Mortality in the Non‐surgically Treated Subgroup. Table S7: Bivariable Predictors of the Composite Adverse Clinical Outcome in the Non‐surgically Treated Subgroup. Table S8: Clinical Outcomes According to Surgical Treatment Status. Table S9: Clinical Outcomes by RVSWI Groups.